Company Littlepharm Srl with Fiscal Code 10110809
recorded a turnover of 2024 of
64.193,
with a net profit of
-6.612
and having an average number of employees of
1.
The company operates in the field of Comerţ cu ridicata nespecializat having the NACE code 4690.
Sales - Ron
Sales, Profit, Employees, Total Income, Financial Results -
Littlepharm Srl
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Sales - EUR
87.020
101.643
97.724
62.991
63.145
65.016
82.876
88.978
98.908
64.193
Total Income - EUR
87.259
101.725
97.732
63.149
63.246
65.075
82.880
89.075
109.853
65.295
Total Expenses - EUR
82.679
92.579
87.228
60.303
61.237
60.897
73.398
81.142
92.493
71.001
Gross Profit/Loss - EUR
4.580
9.146
10.504
2.845
2.009
4.178
9.482
7.933
17.360
-5.706
Net Profit/Loss - EUR
3.483
6.428
7.585
952
1.358
3.556
8.799
7.176
16.416
-6.612
Employees
0
0
0
0
1
1
1
1
1
1
The table presents the most important indicators of the company from the Profit and Loss Account for the last 10 years of activity as found at the Ministry of Finance. The data provides the evolution of the company during this period regarding the increases and possibly decreases recorded.
In the last year of activity, the sales decreased by -34.7%, from 98.908 euro in the year 2023, to 64.193 euro in 2024.
The Net Profit decreased by -16.324 euro, from 16.416 euro in 2023, to 0 in the last year.
Check the financial reports for the company - Littlepharm Srl
Financial Rating - LITTLEPHARM SRL
See the company's note based on the submitted financial data, relative to the industry of which it is a part.
Financial Rating
Payment Limits - Littlepharm Srl
See the company's payment capacity for situations in which you conclude contracts with payment terms.
Check Payment Limits
Prob. of insolvency - Littlepharm Srl
It determines the risk of insolvency based on the submitted accounting balance.
Insolvency Probability
Financial Reports - Littlepharm Srl
Check all the financial reports of the company and know the risks in collaboration with it.
Check Financial Reports
Financial Analysis Reports provide a clear and comprehensive view of a company's financial activity. In addition to presenting financial data, the reports analyze this data so that any user can understand whether the results are positive or less favorable. The Financial Rating provides an analysis based on the most important financial ratios, including liquidity, solvency, and profitability. Payment Limits represent the maximum amounts for which a company can offer goods or services on credit to its clients. The Probability of Insolvency presents the theoretical probability that a company may not be able to meet its financial obligations towards its creditors, i.e., suppliers and financial institutions.
The table presents the company's Balance Sheet structure for the last 10 years. Current Assets recorded a value of
22.867 euro in 2024 which includes Inventories of
7.597 euro, Receivables of
2.811 euro and cash availability of
12.460 euro.
The company's Equity was valued at
51.214 euro, while total Liabilities amounted to
9.885 euro.
Equity decreased by -6.612 euro, from 58.151 euro in 2023, to 51.214 in 2024.
Similar services useful for checking companies and business development.
SellNet
Get the contact details for any company and get in touch with it.
Sectoral Studies
Knows the market and develops its own development strategies according to sectorial data.
Databases
Export in excel files the data of the companies selected according to the desired criteria.
Import - Export
Find importers and exporters according to the type of activity and the countries in which they carry it out.
Similar services represent services associated with companies that allow for a better analysis of clients and suppliers. Company Contacts help you get in touch with the desired companies. Sector Studies provide an overview of an industry, the most important competitors, and the geographical distribution of companies. Company Lists allow you to attract new clients, while Import-Export services give you access to companies engaged in such activities.
Comments - Littlepharm Srl